Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR4 | P51679 | 2/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR7 | P34969 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | STAT1 | P42224 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21928857 | 0.79 | MEN1 (0.32) | ALDH1A1 | |
| SCHEMBL19575790 | 0.71 | HTR1A (0.33) | CCR4HTR1AHTR2AHTR7ALDH1A1 | |
| SCHEMBL12310544 | 0.67 | — | — | |
| SCHEMBL2608448 | 0.67 | LMNA (0.43) | CCR4HTR1AHTR2AHTR7ALDH1A1 | |
| SCHEMBL5767335 | 0.66 | — | — | |
| SCHEMBL5775322 | 0.66 | HTR1A (0.41) | CCR4HTR1AHTR2AHTR7ALDH1A1 | |
| SCHEMBL2736380 | 0.66 | HTR1A (0.41) | CCR4HTR1AHTR2AHTR7ALDH1A1 | |
| SCHEMBL4573687 | 0.66 | HTR1A (0.41) | CCR4HTR1AHTR2AHTR7ALDH1A1 | |
| SCHEMBL5908628 | 0.66 | HTR1A (0.41) | CCR4HTR1AHTR2AHTR7ALDH1A1 | |
| SCHEMBL28170638 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11130754-B2 | Substituted benzamides as RIPK2 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-09-28 | — | — | US | disclosed |
| US-20190048000-A1 | HETEROARYL CARBOXAMIDE COMPOUNDS AS INHIBITORS OF RIPK2 | BOEHRINGER INGELHEIM INT (DE) | 2019-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190048000-A1 | HETEROARYL CARBOXAMIDE COMPOUNDS AS INHIBITORS OF RIPK2 | RIPK2, RIPK1, RIPK4 | CCR4 3850/4885HTR1A 2188/4885HTR2A 1583/4885 |
| US-11130754-B2 | Substituted benzamides as RIPK2 inhibitors | RIPK2, RIPK4, RIPK1 | CCR4 3577/4885HTR1A 3511/4885HTR2A 2820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.